Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...

Amgen still needs to show that the reduction in Lp(a) is accompanied by lower rates of cardiovascular outcomes, and will endeavour to show that in its phase 3 programme which will start to enrol a ...